Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune modulatory effects of oncogenic KRAS in cancer
Shaima’a Hamarsheh, Olaf Groß, Tilman Brummer, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 272

Showing 51-75 of 272 citing articles:

Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage
Camille Ternet, Christina Kiel
Cell Communication and Signaling (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 41
Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine
Nicolas D. Huyghe, Elena Benidovskaya, Philippe Stevens, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2241-2241
Open Access | Times Cited: 37
Constitutive Activation of the Tumor Suppressor p53 in Hepatocytes Paradoxically Promotes Non–Cell Autonomous Liver Carcinogenesis
Yuki Makino, Hayato Hikita, Kenji Fukumoto, et al.
Cancer Research (2022) Vol. 82, Iss. 16, pp. 2860-2873
Open Access | Times Cited: 34
Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer
Hiroyuki Araki, Hiroshi Tazawa, Nobuhiko Kanaya, et al.
Molecular Therapy — Oncolytics (2022) Vol. 27, pp. 3-13
Open Access | Times Cited: 32
The role of KRAS splice variants in cancer biology
Cristina Nuevo‐Tapioles, Mark R. Philips
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 32
Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer
Jashodeep Datta, Anna Bianchi, Iago De Castro Silva, et al.
Oncogene (2022) Vol. 41, Iss. 28, pp. 3640-3654
Open Access | Times Cited: 29
RAS degraders: The new frontier for RAS-driven cancers
Taylor E. Escher, K.J.F. Satchell
Molecular Therapy (2023) Vol. 31, Iss. 7, pp. 1904-1919
Open Access | Times Cited: 19
Strategies for Heating Up Cold Tumors to Boost Immunotherapies
Daniel J. Zabransky, Mark Yarchoan, Elizabeth M. Jaffee
Annual Review of Cancer Biology (2023) Vol. 7, Iss. 1, pp. 149-170
Closed Access | Times Cited: 16
Benefits and Pitfalls of a Glycosylation Inhibitor Tunicamycin in the Therapeutic Implication of Cancers
Snigdha Banerjee, Affan A. Ansari, Sunil P. Upadhyay, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 395-395
Open Access | Times Cited: 7
Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC
Chiara Musiu, Francesca Lupo, Antonio De Agostini, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Jie Yang, Qiao-Li Wang, Guannan Wang, et al.
Cell Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 6
Revolutionizing Cancer Detection: Harnessing Quantum Dots and Graphene-Based Nanobiosensors for Lung and Breast Cancer Diagnosis
Soheil Sadr, Abbas Rahdar, Sadanand Pandey, et al.
BioNanoScience (2024) Vol. 15, Iss. 1
Closed Access | Times Cited: 6
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
Alice Indini, Erika Rijavec, Michele Ghidini, et al.
Pharmaceutics (2021) Vol. 13, Iss. 5, pp. 653-653
Open Access | Times Cited: 40
Comprehensive analysis to identify DLEU2L/TAOK1 axis as a prognostic biomarker in hepatocellular carcinoma
Yi Shi, Dandan Zhang, Ji‐Bin Liu, et al.
Molecular Therapy — Nucleic Acids (2021) Vol. 23, pp. 702-718
Open Access | Times Cited: 39
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
Colin R. Lindsay, Marina Chiara Garassino, Ernest Nadal, et al.
Lung Cancer (2021) Vol. 160, pp. 152-165
Open Access | Times Cited: 37
Persistent Inflammatory Stimulation Drives the Conversion of MSCs to Inflammatory CAFs That Promote Pro-Metastatic Characteristics in Breast Cancer Cells
Linor Rubinstein-Achiasaf, Dina Morein, Hagar Ben-Yaakov, et al.
Cancers (2021) Vol. 13, Iss. 6, pp. 1472-1472
Open Access | Times Cited: 33
A Comprehensive Analysis of the Glutathione Peroxidase 8 (GPX8) in Human Cancer
Zhijing Ren, Yu He, Qinqin Yang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 27
Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
Thomas Yul Avery, Natalie Köhler, Robert Zeiser, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 26
Integrated multi-omics characterization of KRAS mutant colorectal cancer
Wei Chong, Xingyu Zhu, Huicheng Ren, et al.
Theranostics (2022) Vol. 12, Iss. 11, pp. 5138-5154
Open Access | Times Cited: 25
Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer
Jorien B.E. Janssen, Jan Paul Medema, Elske C. Gootjes, et al.
Cancer Treatment Reviews (2022) Vol. 109, pp. 102433-102433
Open Access | Times Cited: 24
The KRAS-Mutant Consensus Molecular Subtype 3 Reveals an Immunosuppressive Tumor Microenvironment in Colorectal Cancer
Pariyada Tanjak, Amphun Chaiboonchoe, Tharathorn Suwatthanarak, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1098-1098
Open Access | Times Cited: 15
Small molecular inhibitors for KRAS-mutant cancers
Xuan Wu, Wenping Song, Cheng Cheng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
CircIFNGR2 enhances proliferation and migration of CRC and induces cetuximab resistance by indirectly targeting KRAS via sponging to MiR-30b
Qi Zhang, Yifeng Zheng, Jiajia Liu, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 13
Cancer Therapeutic siRNA Delivery and Imaging by Nitrogen- and Neodymium-Doped Graphene Quantum Dots
Alina Valimukhametova, Bong Lee, Ugur C. Topkiran, et al.
ACS Biomaterials Science & Engineering (2023) Vol. 9, Iss. 6, pp. 3425-3434
Open Access | Times Cited: 13
Novel strategies optimize immunotherapy by improving the cytotoxic function of T cells for pancreatic cancer treatment
Wenhao Luo, Jun Wang, Hao Chen, et al.
Cancer Letters (2023) Vol. 576, pp. 216423-216423
Open Access | Times Cited: 13

Scroll to top